<table>
<thead>
<tr>
<th>Title</th>
<th>Molecular mechanisms of liver regeneration and protection for treatment of liver dysfunction and diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Fujiyoshi, Masato; Ozaki, Michitaka</td>
</tr>
<tr>
<td>Citation</td>
<td>Journal of Hepato-Biliary-Pancreatic Sciences, 18(1), 13-22</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2011-01</td>
</tr>
<tr>
<td>Doc URL</td>
<td><a href="http://hdl.handle.net/2115/44870">http://hdl.handle.net/2115/44870</a></td>
</tr>
<tr>
<td>Rights</td>
<td>The original publication is available at <a href="http://www.springerlink.com">www.springerlink.com</a></td>
</tr>
<tr>
<td>Type</td>
<td>article</td>
</tr>
<tr>
<td>File Information</td>
<td>JHBPS18-1_13-22.pdf</td>
</tr>
</tbody>
</table>

Hokkaido University Collection of Scholarly and Academic Papers: HUSCAP
Molecular mechanisms of liver regeneration and protection
- for treatment of liver dysfunction/diseases -

Masato Fujiyoshi and Michitaka Ozaki

Department of Molecular Surgery,
Hokkaido University School of Medicine,
N-15, W-7, Kita-ku, Sapporo, Hokkaido, 060-8638 Japan

Key words: liver regeneration, liver protection, apoptosis, IL-6/STAT3,
PI3-K/PDK1/Akt

Received on December 31, 2009.

Correspondence to:
Michitaka Ozaki M.D., Ph.D.
Department of Molecular Surgery,
Hokkaido University School of Medicine,
N-15, W-7, Kita-ku, Sapporo, Hokkaido, 060-8638 Japan
E-mail address: ozaki-m@med.hokudai.ac.jp
Telephone: +81 11 706 7063
Fax: +81 11 717 7515
Abstract

Liver regeneration is a necessary process which most liver damage depends on for its recovery. It is achieved by a complex interaction network consisting of liver cells (hepatocytes, Kupffer cells, sinusoidal endothelial cells, hepatic stellate cells and stem cells) and extra-hepatic organs (thyroid gland, adrenal gland, pancreas, duodenum and autonomous nervous system). The restoration of liver volume depends on the hepatocyte proliferation which includes initiation/proliferation/termination phases.

Hepatocytes are ‘primed’ mainly by Kupffer cells via cytokines (IL-6 and TNF-alpha) and then ‘proliferation’ and ‘cell growth’ of hepatocyte are induced by the stimulations of cytokines and growth factors (HGF and TGF-alpha). Liver regeneration is achieved by cell proliferation and cell growth, where IL-6/STAT3 pathway and PI3-K/PDK1/Akt pathway play pivotal roles, respectively. IL-6/STAT3 pathway regulates hepatocyte proliferation via cyclin D1/p21 and protects against cell death by up-regulating FLIP, Bcl-2, Bcl-xL, Ref1 and MnSOD. PI3-K/PDK1/Akt is known to be responsible for regulation of cell size via its downstream molecules such as mTOR in addition to its survival, anti-apoptotic and anti-oxidative properties.

Although the molecular mechanisms of liver regeneration have been actively studied, it is required to elucidate and leverage the mechanisms of liver regeneration for the
sufficient treatment of liver diseases.
Introduction

Even though we are in the advanced era in hepato-biliary-pancreatic surgery, the recovery from most liver damage depends mainly on the innate regenerative capacity of liver. The regenerative processes of liver are complicated. It can be induced/triggered not only by the primary reduction of liver mass such as partial hepatectomy (PH) or liver transplantation with small-for-size grafts, but by the secondary reduction of viable liver mass induced by injurious liver diseases such as viral hepatitis, drug injury or steatosis[1]. In such pathological situations, liver regeneration often progresses in parallel to gradual damage of liver parenchyma and structure. Therefore, for the sufficient treatment of liver diseases with the maximal liver regeneration/function, it is required to elucidate and leverage the biological mechanisms of protection as well as regeneration of the liver under normal and pathological situations.

In this review, we describe the molecular mechanisms of liver regeneration and protection in rodents and discuss the functions of some critical molecules (pathways) of hepatocytes. Especially, we focus on the distinct roles of IL-6/Jak/STAT3 pathway and PI3-K/PDK1/Akt pathway on cell proliferation, growth (increase of cell size) and protection (anti-oxidant and -apoptosis) during liver regeneration.
Molecular mechanisms of liver regeneration

General concepts on extra-/intra-hepatic regulation of liver regeneration

Liver is composed of a various types of cells, hepatocytes, Kupffer cells, sinusoidal endothelial cells (SECs), hepatic stellate cells (HSCs) and stem cells[2], which develop complex network with intimate interactions inside the liver[3]. And the well organized intra-hepatic network is functionally connected with the extra-hepatic organs throughout the body such as thyroid gland[4-5], adrenal gland[6-7], pancreas[8], duodenum[9] and autonomic nervous system[10]. The extra-hepatic organs and systems synchronously and cooperatively regulate the functions/behaviors of liver and liver cells through some hormones (insulin, glucagon, T3, norepinephrine and somatostatin) and growth factors (EGF).

The intercellular interactions between liver cells are mediated by growth factors (HGF, TGF-alpha and beta) and cytokines (IL-6, TNF-alpha and IFN-gamma )[2-3, 11]. This inter-dependent control system seemingly achieves the precise and robust regulation of liver regeneration. These growth factors and cytokines will immediately and synchronously evoke various cellular events essential for liver regeneration/protection by sending signals finally to hepatocytes. This network system of liver regeneration is possibly comprehended as the spatio-temporal dynamic changes
of the signal transduction systems in the liver. The temporal development of the specifically activated signaling pathways during liver regeneration may be divided into three phases, initiation phase, proliferation phase and termination phase[2]. In each phase, some characteristic cellular/molecular events have been observed. However, the precise signaling pathways in hepatocytes and their functional roles during initiation, proliferation and termination of liver regeneration have not been understood well. We will focus on the roles of signals, especially IL-6/Jak/STAT and PI3-K/PDK1/Akt about initiation/proliferation/protection in liver regeneration in the following sections.

1. Priming of hepatocytes in liver regeneration

The restoration of liver volume depends primarily on the proliferation of hepatocytes. Under non-pathological and static conditions, hepatocytes are in a quiescent state (G0 phase) and hardly undergo mitosis responding to growth factors. Once hepatocytes are primed, they show high reactivity to the mitogens[12]. This process largely depends on the interactions between hepatocytes and non-parenchymal cells (Kupffer cells, SECs, HSCs) via cytokines such as TNF-alpha and IL-6. At the beginning of initiation phase of liver regeneration, Kupffer cells are activated by the stimulations such as LPS[13], C3a, C5a[14] and ICAM[15], and then start to produce and secrete TNF-alpha. Kupffer cells express TNF receptor 1 (TNFR1) on their surface.
and activate themselves in the autocrine fashion. TNF-alpha/TNFRI signaling circuit of Kupffer cells is mainly mediated by NF-kB [16]. Because the promoter region of the IL-6 gene contains an NF-kB binding site, IL-6 also can be produced by the activated Kupffer cells. TNF-alpha and IL-6 secreted by the activated Kupffer cells is possibly involved in the priming process at the initiation phase, which enables hepatocytes to respond to ‘proliferation signal’ by the growth factors and/or directly to undergo mitosis[12, 17]. These interactions between hepatocytes and non-parenchymal cells (especially Kupffer cells) are mediated by cytokines such as TNF-alpha and IL-6, and achieve the priming process; G0/G1 transition of hepatocytes in other words. IL-6 also plays a lot of other important roles in liver regeneration inducing hepatic production of hepatocyte growth factor (HGF)[17], which acts as a mitogen of hepatocytes and protecting hepatocytes from apoptosis. Deficiency of IL-6 gene leads to impairment of liver regeneration characterized by liver necrosis and failure[18]. The IL-6 signaling plays a pivotal role in liver regeneration, which is mainly mediated by the mitotic transcription factor, signal transducers and activators of transcription-3 (STAT3) (Fig. 1).

2. Proliferation of hepatocytes in liver regeneration

After G0/G1 transition in initiation phase, approximately 95% of hepatocytes
will be recruited into the cell cycle[3] and some actually undergo mitosis in the remnant liver tissue. The progression of cell cycle of hepatocytes after PH largely depends on growth factor signaling, especially HGF/Met and EGF family ligands/EGFR pathways.

HGF is a potent growth factor that is mainly derived from activated HSCs and promotes proliferation and DNA synthesis of hepatocytes in a paracrine fashion [19]. HGF is secreted as an inactive precursor, pro-HGF and stored in the extracellular matrix. The activation of HGF is achieved by fibrinolytic system. The Immediate early induction of urokinase-type plasminogen activator receptor (u-PAR) after PH initiates the activation of the fibrinolytic cascades and then urokinase-type plasminogen activator (u-PA), plasmin and matrix metalloproteinases (MMPs) are activated. Plasmin and MMPs degrade extracellular matrix (ECM) and release pro-HGF from ECM. Then pro-HGF is cleaved into activated form of HGF by u-PA[20]. And through the suppression of this system, Plasminogen Activator Inhibitor (PAI) and Tissue Inhibitor of MetalloProteinases-1 (TIMP-1) can reduce the efficiency of HGF activation[21]. This post-transcriptional control system can supply sufficient amount of HGF immediately after receiving activation signals. HGF promotes the proliferation of hepatocytes by directly binding to its specific tyrosine kinase type receptor, c-met on the surface of hepatocytes. The HGF/c-met signaling is transmitted to its downstream pathways
including Ras-Raf-MEK, ERK1/2[22], PI3-K/PDK1/Akt[23], and mTOR/S6 kinase pathways. And this contributes to liver regeneration by promoting DNA synthesis, cell cycles progression, cell growth and cell protection.

TGF-alpha is another important growth factor in liver regeneration that directly stimulates DNA synthesis in hepatocytes[24-25]. TGF-alpha belongs to Epithelial Growth Factor (EGF) family that includes EGF, heparin binding EGF-like growth factor and amphiregulin[26]. The members of EGF family share the common receptor EGF receptor (EGFR) and can compensate each other’s function. TGF-alpha is secreted by hepatocytes and functions in the autocrine and paracrine fashions. And the production and secretion of TGF-alpha by hepatocytes are promoted by HGF. Similar to c-met, EGFR also promotes cell proliferation and cell growth as a tyrosine kinase receptor (Fig. 1).

3. Progression and maintenance in liver regeneration: roles of cell proliferation and growth in liver regeneration

Enlargement of liver mass is achieved by 1) cell proliferation that is the increase in number of hepatocytes and 2) cell growth that is the increase in size of hepatocytes. Although the mechanism regulating cell proliferation and growth of hepatocytes remains to be completely elucidated, IL-6/STAT3 pathway and
PI3-K/PDK1/Akt pathway definitely play pivotal roles in regulating proliferation and growth of hepatocytes at least in acute liver response after hepatectomy in rodents, respectively (Fig. 2).

3.1. IL-6/STAT3 signal and hepatocyte proliferation / protection

IL-6 sends mitotic signals mainly through STAT3 in hepatocytes and plays crucial roles in liver regeneration. The response of STAT3 to PH is regarded as a trigger of liver regeneration because of its rapid response. DNA-binding of STAT3 is observed within 30 minutes and peaks at 3 hours after PH in mice[27]. In IL-6-deficient mice, this STAT3 activation is almost suppressed[18]. Therefore, it is considered that the activation of STAT3 is induced exclusively by IL-6 signaling in liver regeneration after PH although STAT3 can be activated by other cytokines such as G-CSF[28] and leptin[29] in other situations.

IL-6/STAT3 signaling pathway is composed of IL-6 receptor, gp130, receptor-associated Janus kinase (Jak) and STAT3. IL-6 receptor forms a complex with two molecules of gp130. After the recognition of IL-6, gp130 immediately transmits IL-6 signal into hepatocytes. gp130 possesses consensus sequence YxxQ motif that is recognized by Src homology 2 (SH2) domain of STAT3 on its cytoplasmic domain[30]. Jak is a phosphorylating enzyme that is responsible for the activation of gp130 and
STAT3. It is bound to the cytoplasmic domain of gp130 in an inactive form and activated by reciprocal phospholyration after IL-6 binding. STAT3 commonly pre-exists in an inactive form and is activated by Jak. STAT3 consists of five functional domains, amino terminal, coiled-coil domain, DNA binding domain, SH2 domain and transcriptional activation domain[31]. Activated monomers of STAT3 must form dimers to exert their transcriptional function. The dimerization of STAT3 depends only on these reciprocal interactions between the phosphor-tyrosine (Y705) of a monomer of STAT3 and the arginyl residue (R608) in the SH2 pocket of another monomer. The IL-6/STAT3 signaling is transmitted in the following manner[32-34]. The spatial arrangement of IL-6 receptor and gp130 proteins is changed by IL-6 binding to its receptor. Jaks are arranged closer to each other and consequently they phosphorylate and activate their counterparts each other. Activated form of Jak can phosphorylate the tyrosine within the YxxQ motif of gp130. The inactive form of STAT3 is recruited to gp130 by the interaction between phosphor-tyrosine on YxxQ motif of gp130 and SH2 domain of STAT3. Jak induces activation of STAT3 through phosphorylation of tyrosine (Y705). Activated STAT3 is released from gp130 and dimerized through the interaction between its SH2 domain and phosphor-tyrosine on its counterpart. STAT3 dimer then translocates to nucleus and regulates the expression of its target genes (Fig. 3).
The main function of STAT3 in liver regeneration is to promote hepatocyte proliferation. To elucidate the mechanisms by which STAT3 regulates proliferation, liver specific STAT3 deficient mice were created[35], because systemic STAT3 deficient mice were early embryonic lethal[36]. In the liver-specific STAT3 knockout mice, DNA synthesis and mitotic activity of hepatocytes after partial PH is reduced significantly. Among the proteins involved in hepatocyte proliferation, the expressions of cyclin D1 and cyclin E usually occurring within 72 hours after PH is also significantly decreased in liver-specific STAT3 deficient mice. Constitutively dimerized and activated STAT3 (STAT3-C) similarly contributes to analysis of the STAT3 function. Transfection of the STAT3-C gene in fibroblasts induces transcription of cyclin D1, Bcl-XL and c-myc[37]. Furthermore, mitogenic effect of STAT3 is demonstrated in rat 20% partial liver transplant model. In this experiment, liver graft transfected with the Stat3-C gene during cold preservation showed a greater enlargement of liver graft and hepatocyte proliferation with reduced post-transplant graft damage than the non-treated graft[11].

One of the well investigated mechanisms by which STAT3 promotes liver regeneration is the control of cell cycle progression from G1 to S phase[38]. Cell cycle is considered to be strictly regulated by the periodic expression pattern of cyclins and CDKs. Cell cycle is a sequential process that consists of four conceptual phases, gap 1
phase (G1), synthesis phase (S), gap 2 phase (G2) and mitosis phase (M). Hepatocytes move from quiescent state (G0) into starting point of cell cycle (G1) during the initiation phase, and then they encounter the restriction point in late G1 phase[39]. The expression of G1 cyclins can permit hepatocytes to override the restriction point and enter into S phase. The G1 cyclins include cyclin D and E and the expression of cyclin D1 is regulated by STAT3[35]. Cyclin D1 binds to CDK4/6, which partially phosphorylates Rb protein that binds to E2F to repress its transcriptional activity. Although cyclin D1/CDK4 or 6 complex is not able to derepress E2F completely, partially activated E2F can induce the expression of cyclin E. Then cyclin E forms a complex with CDK2 leading to complete phosphorylation of Rb protein and activation of E2F. Fully activated E2F induces the expression of its target genes that is responsible for transition from G1 to S phase[40-41]. Thus STAT3 regulates G1/S transition of hepatocytes through the control of cyclin D1 expression (Fig 3).

Although apoptosis may be an essential process for the liver to maintain its homeostasis, to prevent hepatic neoplasms and autoimmune diseases and to eliminate viruses, inappropriate apoptotic responses induce tissue destruction and eventually liver dysfunction. In liver surgery including liver transplantation, graft preservation, temporal vascular occlusive maneuver or hemodynamic instability are accompanied by hepatic
ischemia/reperfusion (I/R) and eventually induce apoptosis. These pathological signals are mediated by death receptor pathway, mitochondrial pathway, p53 pathway and MAPK pathway[42]. Apoptosis contributes to pathogenesis and progression in some liver diseases. Hepatitis viruses activate apoptotic signals with immunological mechanisms and/or direct viral effects[43]. Liver damage by HBV infection is alleviated by the blockade of TRAIL pathway[44-45] and HCV promotes apoptosis of hepatocytes by increasing the expression of Fas on hepatocytes and Fas-ligand (FasL) on T cells. And the viral protein such as HBV X protein[46] and HCV core protein[46-47] can induce apoptosis directly interacting with the cytoplasmic domains of death receptors and p53. In fulminant hepatic failure, caspase-3, Fas/FasL and TNF alpha/TNFR is upregulated in liver[48]. Therefore, liver damage (apoptosis of hepatocyte) may progress simultaneously with liver regeneration to some degree, depending on the underlying liver disease.

The target genes of STAT3 include anti-apoptotic genes, FLIP, Bcl-2 and Bcl-xL and therefore STAT3 potentially possesses the anti-apoptotic capacity[49]. Apoptosis is initiated by binding of death ligands such as FasL and TRAIL to their specific death receptors. And then caspase-8, -10 and FADD is recruited into the cytoplasmic death domains of death receptors to form the death inducing signaling
complex (DISC) leading to the activation of caspase-8 and -10. FLIP inhibits this recruitment of caspase-8 and-10 competitively[50]. Cleaved and activated caspase-8 can propagate its signal directly to caspase-3 or through mitochondrial pathway mediated by BH3 only proteins such as Bid[51]. Then apoptotic proteins, Bax and Bak induces mitochondrial outer membrane permeabilization (MOMP) and anti-apoptotic proteins, Bcl-2 and Bcl-xL impair this step[52]. Interestingly, STAT3 is also known to possess anti-oxidative capacity. Hypoxia/reoxygenation (H/R) and I/R can induce apoptosis of hepatocytes in a redox-dependent manner, where generation of reactive oxygen species (ROS) in hepatocytes will activate redox-sensitive caspases such as caspase-3/-9. STAT3 also upregulates genes of Ref-1[53] and Mn-SOD[54] that protects hepatocytes from ROS-mediated apoptotic cell death (Fig 4).

As mentioned above, STAT3 largely contributes to liver regeneration through its cell proliferative and protective properties. However, it may possibly impair liver regeneration inversely in some situations. Fatty liver (steatosis of hepatocytes) is a known risk factor of liver surgery such as PH[55-56], liver transplantation[57-59] and donor operation[60-61]. The impairment of hepatocyte proliferation is thought to be due to the effect of steatosis in part. In steatotic liver, cell cycle-related proliferative disorders occur at mid-S phase. Reduced expression of Wee1 and Myt1 kinases may
maintain Cdc2 in an unphosphorylated state and block cell cycle progression in mid-S phase[62]. Some researchers reported that in ob/ob (or db/db) mice with fatty liver, a higher level of phospho-STAT3 was observed than normal mice. And PH phosphorylated STAT3 far more in these mice than normal mice. Despite STAT3 was markedly phosphorylated, DNA synthesis and transcription of cyclin D1 in ob/ob mice liver remained at lower level. It seems strange that STAT3 activation was positively correlated with expression of p21[63]. p21 is a CDK inhibitor (CKI) protein that inhibits G1/S progression binding to cyclin D1/CDK4 of 6 complex in hepatocytes[64]. 

$p21$ gene, upregulated by STAT3, may impair proliferation of hepatocytes in some situations[65], or inversely may potentially afford scaffolding effect for STAT3-mediated cell proliferation.

As such, the biological significance of STAT3 is still unclear at present. The functions of STAT3 and its responsiveness, however, are definitely regulated by the patho-physiological situations that the liver is suffering. They may be affected by the metabolic states (such as steatosis and metabolic syndrome), age and/or redox states (Fig 3).

**3.2. PI3-K/PDK1/Akt pathway and hepatocyte growth**

PI3-K/PDK1/Akt pathway has been known as a survival pathway functioning
in anti-apoptosis[66-68], anti-oxidation[69-70] and protein synthesis. Recently, it was revealed that PI3-K/PDK1/Akt pathway is responsible for regulating cell growth and determining cell size / functions[71-76]. PI3-K/PDK1/Akt signals are initiated by the activation of the receptor tyrosine kinases (RTKs) or receptors coupled with G proteins by IL-6[77], TNF-alpha[78-79], HGF[23], EGF[80-81], TGF-alpha[81] or many other signaling molecules.

PI3-K is classified in three categories, class I, II and III[82] by their structure. Class I PI3-Ks are kinases composed of a catalytic subunit of p110 and an adaptor/regulatory subunit of p85. PI3-K exclusively phosphorylate phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to form phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3) in vivo [83-84]. This phosphorylation capacity of PI3-K is negated by phosphatase and tensin homolog deleted on chromosome 10 (PTEN) that degrades PI-3,4,5-P3 to PI-4,5-P2 conversely[85]. PI-3,4,5-P3 provides a phospholipid binding substrates for PDK1 and Akt, and recruits them to the site on the membrane where the PI-3,4,5-P3 is fixed[86].

Akt, a down-stream molecule of PI3-K/PDK1, is a serine/threonine kinase that consists of a kinase domain, a hydrophobic domain and a pleckstrin homology domain which possesses the affinity for PI-3,4-P2 and PI-3,4,5-P3. Akt can be activated by
phosphorylation at two sites, threonine residue (T308) in the activation loop of kinase domain, and serine residue (S473) in the hydrophobic domain. Although phosphorylation at T308 is sufficient for the activation of Akt, full activation needs the phosphorylation of both T308 and S473[87-90]. PDK1 mainly activates Akt by phosphorylating threonine residue at 308[91], and PDK2, not determined yet, phosphorylates Akt at serine.

Mammalian target of rapamycin (mTOR) is one of the important downstream molecules of Akt for cell growth[92]. The activation of mTOR is promoted by Akt in a suppressive manner via TSC1, TSC2 and Rheb suppression. Akt phosphorylates TSC2 to inhibit function of the TSC1-TSC2 complex and then to inhibit Rheb function. Rheb positively modulates the function of mTOR[93]. mTOR suppresses and activates eIF4E inhibiting 4E-BP1 activity and it also activates S6K1 and S6K2. These downstream effectors of mTOR regulate protein synthesis, cell size, cell cycle progression, glucose homeostasis and survival of newborn[94]. And PDK1 can activate S6K1 and S6K2 directly in addition to the activation of Akt (Fig. 5).

We previously reported that PI3-K/PDK1/Akt pathway coexists with STAT3 pathway and can compensate for the insufficiency of its counterpart in some specified conditions during liver regeneration. In liver specific STAT3-knockout mice, no
significant difference was observed in macroscopic liver regeneration, compared to the control mice. Although the expression of cyclin D1 and therefore mitosis of hepatocyte were definitely impaired, the liver size of STAT3-knockout mice 3 and 14 days post-70% PH was almost equal to those of normal mice. This strange observation about liver regeneration was explained by the enlarged size of each hepatocyte. The cell size of hepatocyte in STAT3-knockout liver was significantly larger than that in normal liver 72 hours post-PH. And in 14 days after PH, the cell size of STAT3-knockout liver was normalized. Along with the enlarged cell size (cell growth), the marked phosphorylation of Akt and its downstream molecules, p70S6K, mTOR and GSK-3 beta was observed[95].

To elucidate the mechanism of ‘cell size regulation’ during liver regeneration, we next generated liver specific PDK1-knockout mice. In PDK1-knockout mice, phosphorylation of threonine residue (T308) of Akt was impaired and therefore the phosphorylation/activation of p70S6K, mTOR was decreased. These PDK1-knockout mice couldn’t endure 70% PH, and macroscopic liver regeneration 3 and 14 days after 30% PH was severely impaired. This phenotype was normalized by transfection of the adenovirus vector encoding PDK1 interacting fragment (pif) pocket mutant of Pdk1 that signals exclusively to Akt but not to p70S6K or any others[96-97]. Based on these observations, PDK1 was evidenced to contribute to early phase of liver regeneration
promoting cell growth via Akt activation. These experiments provided another novel insight to the understandings of molecular/cellular mechanisms in liver regeneration.

There are some other reports supporting the importance of PI3-K/PDK1/Akt-mediated growth in liver. Stiles et al. reported that liver-specific deletion of PTEN induced marked phosphorylation of Akt, where significant hepatomegaly was observed with increased size of cell size[98]. Mullany et al. also demonstrated the cell growth induced by Akt. They transiently over-expressed Akt and cyclinD1 in the liver of mice by transfecting an adenovirus vector. While the transfection of cyclinD1 promoted DNA synthesis/cell proliferation and induced liver growth, far tremendous liver growth was observed in Akt-transfected mice. In the Akt-transfected liver, DNA synthesis was observed similar to the control liver, but the evidently increased size of liver cells were confirmed in flow cytometrical analysis[99]. Jackson et al. reported that inhibition of PI3-K leads to significant decrease in hepatocyte proliferation, especially at the earliest time points. They used wortmannin and siRNA targeting p85 alpha and p110 alpha to inhibit PI3-K activity. Liver regeneration in early period after hepatectomy was impaired significantly in the mice pre-treated with siRNA and wortmannin 24 hours prior to PH. In the PI3-K-inhibited liver, the aggregation of Kupffer cells after PH was reduced and the serum levels of
cytokines, IL-6 and TNF-alpha were also decreased. They uniquely concluded that PI3-K contributes to liver regeneration especially early after PH by promoting migration of Kupffer cells to the site of regeneration, priming of hepatocytes with cytokines (IL-6 and TNF-alpha) and DNA synthesis of hepatocytes[100]. The above observation may support our observation on PI3-K/STAT3 axis that PI3-K directly sends a mitogenic signal to STAT3 and promotes hepatocyte proliferation directly or indirectly.

**Conclusion**

Although the precise mechanisms of liver regeneration are still unknown, the accumulation of evidences prompted us to study and understand the mechanisms of impaired regeneration in the diseased liver from the aspect of molecular biology. As some mechanisms are presumed to be responsible for the impairment of regeneration in steatotic liver, it is suggested that some of aberrant behavior of biological molecules cause liver dysfunction.

Liver regeneration has come to be regarded as an integration of multiple separated processes, including cell proliferation and growth. Here, we propose the schematic mechanisms of molecular regulation of liver regeneration, focusing on IL-6/STAT3 and PI3-K/PDK1/Akt pathways in hepatocytes (Fig. 6). Because the liver is
composed of mortal cells, the liver is in a state of dynamic equilibrium even when it is in quiescent state. Therefore, cell death may play an important role in regulation of liver regeneration especially termination phase. The studies on cell death and liver regeneration have just begun but the cell death may be the third piece of understanding liver regeneration hereafter.
Kupffer cells primes hepatocytes via cytokines such as TNF-alpha and IL-6 (initiation phase). Then HGF released from HSC and ECM and activated by fibrinolytic system, leads to proliferation of hepatocytes (proliferation phase).
Liver regeneration is basically achieved by the combination of two distinct manners, cell proliferation and growth. Cell proliferation (increase in number of hepatocytes) is mediated by IL-6/STAT3 pathway and cell growth (increase in size of hepatocytes) by PI3-K/PDK/Akt pathway.

Fig. 2  Cell proliferation and cell growth in liver regeneration
STAT3 is activated by IL-6 signal through Jak/STAT pathway in hepatocytes. STAT3 promotes the expressions of cyclin D1 and p21 to control the progression of cell cycle.
Fig. 4  Jak/STAT and anti-apoptosis/-oxidation

STAT3 protects hepatocytes from cell death by inducing anti-apoptotic proteins (FLIP, Bcl-2 and Bcl-xL) and anti-oxidation proteins (Ref-1 and MnSOD).
Fig. 5  PI3-K/PDK1/Akt and mTOR for cell growth, survival and protein synthesis

PI3-K/PDK1/Akt pathway is responsible for the determination of sizes of hepatocytes through its downstream effectors (mTOR).
Fig. 6 Two major signaling pathways in liver regeneration: IL-6/Jak/STAT3 and PI3-K/PDK1/Akt for cell growth, survival and protein synthesis.

IL-6/Jak/STAT3 and PI3-K/PDK1/Akt pathways play important roles to achieve multiple processes required for liver regenerations (cell proliferation, growth and protein synthesis).
References

42. Georgiev P, Dahm F, Graf R, Clavien PA. Blocking the path to death:


92. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002 Jun 15;16(12):1472-87.